KEYNOTE-042: PHASE 3 STUDY OF PEMBROLIZUMAB (MK-3475) VERSUS PLATINUM DOUBLET CHEMOTHERAPY AS FIRST-LINE THERAPY FOR PD-L1-POSITIVE NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Lopes, Gilberto [1 ]
Watson, Patricia A. [2 ]
Zhang, Jin [2 ]
Rangwala, Reshma [2 ]
Mok, Tony [3 ]
机构：
[1] Ctr Paulista Oncol E Hcor Onco, Members Oncoclin Brasil Grp, Sao Paulo, Brazil
[2] Merck & Co Inc, N Wales, PA USA
[3] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2014年 / 9卷 / 09期
关键词：
NSCLC; PD-L1; MK-3475; pembrolizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.25
引用
收藏
页码：S192 / S192
页数：1
相关论文
共 50 条
  • [1] Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1-positive advanced non-small cell lung cancer (NSCLC).
    Mok, Tony
    Wu, Yi-Long
    Watson, Patricia A.
    Zhang, Jin
    Rangwala, Reshma A.
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+non-small cell lung cancer (NSCLC): Randomized, open-label, phase 3 KEYNOTE-042 study
    Mok, T.
    Wu, Y. -L.
    Sadowski, S.
    Zhang, J.
    Rangwala, R.
    de Lima Lopes, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 147 - 147
  • [3] Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042
    Mok, T.
    Wu, Y. -L.
    Sadowski, S.
    Zhang, J.
    Rangwala, R.
    Kush, D.
    de Lima Lopes, G.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S142 - S142
  • [4] Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001.
    Rizvi, Naiyer A.
    Garon, Edward B.
    Leighl, Natasha
    Hellmann, Matthew David
    Patnaik, Amita
    Gandhi, Leena
    Eder, Joseph Paul
    Rangwala, Reshma A.
    Lubiniecki, Gregory
    Zhang, Jin
    Emancipator, Kenneth
    Roach, Charlotte M.
    Rutledge, Ruth
    Hui, Rina
    Ahn, Myung-Ju
    Horn, Leora
    Felip, Enriqueta
    Costa, Enric Carcereny
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
    Hui, R.
    Garon, E. B.
    Goldman, J. W.
    Leighl, N. B.
    Hellmann, M. D.
    Patnaik, A.
    Gandhi, L.
    Eder, J. P.
    Ahn, M-J
    Horn, L.
    Felip, E.
    Carcereny, E.
    Rangwala, R.
    Lubiniecki, G. M.
    Zhang, J.
    Emancipator, K.
    Roach, C.
    Rizvi, N. A.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 874 - 881
  • [6] Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC
    Mok, T. S. K.
    Wu, Y-L.
    Kudaba, I.
    Kowalski, D. M.
    Cho, B. C.
    Turna, H. Z.
    de Castro, G., Jr.
    Srimuninnimit, V.
    Laktionov, K. K.
    Bondarenko, I.
    Kubota, K.
    Caglevic, C.
    Karaszewska, B.
    Dang, T.
    Yin, L.
    Penrod, J.
    Lopes, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 38 - 38
  • [7] KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1-positive NSCLC after platinum-based therapy
    Herbst, R. S.
    Kim, D-W.
    Felip, E.
    Perez-Gracia, J. L.
    Garon, E. B.
    Han, J-Y.
    Molina, J.
    Kim, J-H.
    Gervais, R.
    Ahn, M-J.
    Majem, M.
    Fidler, M. J.
    De Castro, G., Jr.
    Garrido, M.
    Lubiniecki, G. M.
    Shentu, Y.
    Im, E.
    Baas, P.
    ANNALS OF ONCOLOGY, 2015, 26 : 162 - 162
  • [8] KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1).
    Brahmer, Julie R.
    Kim, Edward S.
    Zhang, Jin
    Smith, Margaret Marie
    Rangwala, Reshma A.
    O'Brien, Mary E. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer
    Zhou, Yixin
    Zhang, Yaqiong
    Guo, Guifang
    Cai, Xiuyu
    Yu, Hui
    Cai, Yanyu
    Zhang, Bei
    Hong, Shaodong
    Zhang, Li
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 10 (01): : 107 - 115
  • [10] Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.
    Papadimitrakopoulou, Vassiliki
    Patnaik, Amita
    Borghaei, Hossein
    Stevenson, James
    Gandhi, Leena
    Gubens, Matthew A.
    Yang, James Chih-Hsin
    Sequist, Lecia V.
    Ge, Joy Yang
    Bourque, Jennifer
    Bachman, Robert D.
    Im, Ellie
    Gadgeel, Shirish M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345